InMed Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
IMLFF InMed Pharmaceuticals Inc
PNW Pinnacle West Capital Corp
AAPL Apple Inc
NAII Natural Alternatives International Inc
SJMiv.P Invesco BulletShares 2022 Hi Yld Corp Bd ETF
INTC Intel Corp
VAL Valaris PLC
GE General Electric Co
XOM Exxon Mobil Corp
MSFT Microsoft Corp

Health Care : Biotechnology | Small Cap Growth
Based in CanadaCompany profile

InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).

Closing Price
Day's Change
0.0234 (12.58%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Roku stock gains after RBC upgrade

4:13 pm ET October 10, 2019 (MarketWatch)

Shares of Roku Inc. (ROKU) were up 2.5% in after-hours trading Thursday after RBC analyst Mark Mahaney upgraded the stock to outperform from sector perform. He sees the stock as more attractive now that it's fallen about 31% from its recent highs, and he's also drawn to the company's strong positioning and fundamentals. "We believe the Crucial Combo (revenue growth + EBITDA margin) is key in helping to determine fundamental attractiveness in the small-cap 'net sector, and Roku has consistently had one of the highest scores in our coverage," Mahaney wrote. "We view Roku as one of the best derivative plays off of one of the strongest trends in 'net land: over-the-top/streaming, with the company being one of the best-positioned to take share of the very large, underpenetrated $70 billion TV ad spend opportunity." He upped his target on the stock to $155 from $107. Shares have lost 19% over the past month, while the S&P 500 has dropped 1.4%.

-Emily Bary; 415-439-6400;

(END) Dow Jones Newswires

October 10, 2019 16:13 ET (20:13 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.